Immunocellular therapeutics WKN: A0MVAX

Like Billy Beane, Manish Singh, CEO of Immunocellular Therapeutics, has been able to build a leading cancer immunotherapy company with very limited resources. With only a handful of employees and a few million dollars, the company licensed several overlooked technologies from top academic institutions and medical centers in the U.S., and is now developing an extremely promising new cancer immunotherapy for brain tumors.

Cancer immunotherapies are a growing class of drugs that illicit patients’ own immune systems to destroy tumors. The FDA has already approved two cancer immunotherapies: Dendreon’s (DNDN) Provenge for prostate cancer and Bristol Myers Squibb’s (BMY) Yervoy for melanoma. IMUC’s lead product, ICT-107, is a cancer immunotherapy for glioblastoma multiforme (GBM), an extremely deadly form of brain cancer.

In a Phase I study conducted at Cedars-Sinai Medical Center, newly diagnosed GBM patients treated with ICT-107 had a median survival rate of 38.4 months. The median survival rate for similar patients treated with the current standard of care is only 18.4 months. The unprecedented improvement in survival earned ICT-107 a spot on R&D Directions magazine’s Top 100 Investigational Drugs list earlier this year, as well as accolades from other organizations.

Based on the success of the Phase I study, IMUC initiated a multicenter, placebo-controlled, double-blinded Phase II trial in February of this year. Enrollment is proceeding well, and management anticipates interim data as early as the end of 2012 and final results near the end of 2013. The company intends to partner ICT-107 with a major drug company to conduct Phase III trials once the Phase II results are available. The company’s technology can be easily expanded into other cancer indications. Phase I/II trials for pediatric GBM, recurrent GBM, and ovarian cancer could be launched as early as mid-2012.

ImmunoCellular's management has been extremely efficient with its capital. Over the last two years, the company spent less than $7.0 million on operating expenses, most of which was used to fund clinical trials, while the market cap increased about $35 million during the same time period. Investors that bought at 2009 lows have been handsomely rewarded as the stock is up more than 900% since then.

One of the most popular indexes for cancer immunotherapy companies is the Mentor Capital Cancer Immunotherapy Index. It is an index of the leading edge cancer companies. There are 11 companies in the index and just two of the companies have driven all of the performance of the index over the past two plus years. The index is up 33% over the past 115 weeks with just ImmunoCellular Therapeutics and Oncothyreon (ONTY) able to outperform that by returning 417% and 100%, respectively. The company has no debt and about $10 million of cash on its balance sheet, enough cash for at least the next 12 months. Major investors include top healthcare funds, such as DAFNA, Highland Capital, and Strauss Capital.

Institutional investors aren’t the only organizations positive on the stock, research shops Dawson James and Summer Street like it as well. Summer Street has a price target of $8 on the stock, commenting that they expect “significant appreciation” in the stock into the release of the interim results for ICT-107 by the end of 2012. Dawson James has a price target of $5 on the stock and called ICT-107 a “potential blockbuster” cancer vaccine.

Like Billy Beane, IMUC’s CEO, with a very limited budget, has been able to exploit inefficiencies in the market to build one of the most promising organizations in the game. Maybe one day, you’ll even see a book written about IMUC

Also,warten,warten ,warten ...... bis Ende 2012 erstmal,vorher steig ich auch sowieso nicht ein !

Chalifmann  

vollkommene übereinstimmung.
es gilt doch screening & analyse auf die $$$-chancen zu unserem vorteil auszuwerten. kompetenzverdichtung = gleich größere chance! (imho)

im übrigen beobachte ich ab und an eure züge im chessthread, bevorzuge allerdings selbst  physisch am brett zu spielen....und lass bbb doch mal gewinnen, sonst verliert er die freude daran ;-))  

wow, wußte nicht das du so eine berühmtheit bist. hatte heute morgens bereits eine der monumentalen statuen des großen chalifmann III gesehen und bewundert!

Alexza: kennt er die?
CT ist die entwicklung von OBV und MACD nun endlich ganz ordentlich (impo).
da der markt insges. sehr bearish ist und viele investoren davor zurückschrecken, einzusteigen um dann bloß auf hold zu sein, kann ich nicht abschätzen, ob zeitpunkt für longies zum positionsaufbau der richtige ist.
na, guck dir das mal an

http://ih.advfn.com/p.php?pid=nmona&article=49441431
http://ih.advfn.com/p.php?pid=nmona&article=49462449
http://www.alexza.com/  

 

 

schaust hier nie rein und meldest einen verstoß?
wenn du mein posting geistig richtig erfasst hättest, hättest du feststellen können, dass es sich hier nur um die beantwortung einer frage aus post#21 gegangen ist.
xxx wurde weder beworben noch wurde zum kauf an- oder abgeraten!  

> IMMUNOCELLULAR THERAPEUTICS Aktie <
andere Aktien sind im jeweiligen Thread zu besprechen.

Bitte die Forum-Regeln beachten.

http://www.ariva.de/articles/forum/  

tut mir leid, mußt wohl doch eigene plattformen für sämtliche bioscienceunternehmen eröffnen.
na dann...  

ahja, chalifmannIII, eine frage hätte ich an dich.
wenn jemand ein spezielles interesse hat (z.B. ultralong und bedauerlicherweise viel zu hoch reingegangen ist), und verhindern will, das kleinstinvestoren sich den einstieg gut überlegen, was wäre nach durchsicht und analyse von hinweisen u. informationen denn wohl der logische schluß?

hier die IMUC themen  (IMUC = Immunocellular Therapeutics) der jüngsten konferenz:

ImmunoCellular Therapeutics to Present at Second Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference on Octo...
print
Immunocellular Thera (OTCBB:IMUC)
Historical Stock Chart
1 Month : September 2011 to October 2011


ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) ("ImmunoCellular" or the "Company") a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that the company will present at the Second Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference on October 6, 2011 at the New York Academy of Medicine in New York City. The conference will include panel discussions, keynote speakers, and presentations by various individuals and companies engaged in immunotherapeutic cancer research and development, as well as provide the opportunity for key opinion leaders, industry executives, and investors to engage in group and one-on-one discussions.

Manish Singh, Ph.D., President and CEO of ImmunoCellular Therapeutics, will present at the conference at 11:45 am EDT and will discuss the Phase II trial of ICT-107, the Company’s lead candidate for the treatment of glioblastoma.

A corresponding live webcast of the Company presentation will be accessible by visiting the Webcasts and Presentations under the "Investors" section of the IMUC website at www.imuc.com .  

schick mir die links zu den galena und alexza threads auf ariva.de
wid dir schwer möglich sein, außer du eröffnest schnell welche!
wenn dies all deine konstruktiven beiträge hier sind, kannst du sehr auf deine kreativität stolz sein!

Meldung eines Regelverstoßes:
Melder: 0815ax
Zeitpunkt: 09.10.11 15:51
Grund: >>>Bewerbung threadfremder Aktie
== OFFTOPIC in diesem Thread !!!!!
sorry, gibt eigenen Thread zu dieser Aktie, also weshalb hier???  

also,digger2007,hab ich als Threaderöffner nicht auch noch ein Wörtchen mitzureden,hm ? Ich wünsche mir nämlich sehr wohl eine breite diskussion in meinem Thread,insbesondere die aktie Galena hätt ich gerne hier besprochen gesehen,und ich versteh dein ganzes Ttheater nicht,ich habe ausdrücklich darauf hingewsiesen,dass es in diesem Thread nicht nur um immunocellular gehen soll,sondern auch um andere interessante Biotech-microcaps,von "Threadfremd" kann also überhaupt keine Rede sein !!

Chalifmann

P.S. Lady luck,ich habe dein Posting zu Galena leider verpasst,stell es doch bitte noch mal ein .....  

der0815ax petzt das doch sofort und du siehst es wieder nicht.

(der hat großes interesse, dass diese infos nicht publiziert werden. warum auch immer! egal)

muß mal kramen auf harddrive, schicks dir dann via BM. kannst es je nach lust und laune selber einstellen. dich als threadgründer hat er jedenfalls noch nicht gewagt zu verpetzen.

eventuell gründest einen allgem. biotech-thread, dort haben denunzianten [squealer] weder rechtfertigung noch macht.

 

festgemacht anhand konkreter Unternehmen, vergleichende gegenüberstellungen und zukünftige kursperspektiven und -entwicklungen auch interpretierbar für einige andere innovative companies in diesem sektor, wie z.B. IMUC  (IMUC = Immunocellular Therapeutics)

interessante Darstellung über unterschiedliche Pharmaunternehmen aufgrund aktueller CXM-Situation & Kursentwicklung am Yahoo Message Board:

Cardiums pps was incredibly depressed due to FDA delays and lack of belief Excellagen would get approval.  It got approval.   All the shorts (and the odd latecomer who hopes to get in now at a cheaper price) who try to bash Caridum have now is the line - "take temporary profits".  LOL   Anyone else notice that doesn't work so well on a small-cap pharm that just got approval on a large, revenue generating drug? Its because the price just keeps going up and up as it should!   JAZZ was .47 in 2009 while laying stagnant waiting for FDA approval - much like Cardium waited for 2 1/2 years. Today JAZZ closed at 43.71.   I see a lot of similarities between JAZZ and CXM. Do your own DD and you will too. Why I'm going to hold 90%+ of my shares for a long time to come - 1-2 years? More? I know Excellagen will be generating a TON of revenue for a long time to come which will allow Cardium to develop Generex.   Do you DD on Generex. It has the potential to be vastly bigger than Excellagen - which is no small drug in and of itself - 150 million a year is what its only competitor does now. Anyone who knows anything about pharm investing knows how ludicrous the claim that only 10% of revenue in pharm is profit.. It's more along the lines of 60-80%. The great majority of the cost of a drug comes from its development, R&D,trials and clinicals.   Cardium is small cap pharm that has show it can get a major drug, Excellagen, through to approval and now distribution in the coming days.   I believe they also have incredible potential with Generex. Take a look at the clinical phase 1 and phase 2 results and the ongoing research with Generex for yourself. Cardium has the knowledge, ability, wherewithal and now TONS of in house funding to develop a drug of this magnitude. A drug that could do billions in revenue.   Cardium will in time be exponentially bigger than what Excellagen's revenue stream will provide in the coming year- which will be rather large to begin with =)

 

I contacted Dr. Manish Singh, who has been the president and CEO of ImmunoCellular Therapeutics since February of 2008. I was able to ask him some pointed questions about this topic and others.

Q: Some have argued that DNDN's stock was over-valued because the drug has marginal benefits. Can you tell us how your immunotherapy differs from theirs and others?

Dr. Manish Singh, CEO of IMUC: While Dendreon increases survival by 20% in prostate cancer patients (22 months to 26 months), we have seen survival improvement by more than 150% (from 14.6 months for historical standard of care to 38.4 months based on Phase I). In glioblastoma, where the current standard of care drug, Temodar, increases survival by only 2 months, increasing this survival by 2 years, is quite remarkable. If this were validated in a pivotal clinical trial, this would be seismic shift in how you care for glioblatsoma patients. What makes IMUC different is our strategy to target cancer stem cells, widely acknowledged as the roots of cancer. Every tumor mass has a small number of these cells which are responsible for progression of disease even after most of the tumor has been removed by surgery and knocked down by chemotherapy and radiation therapy. We are the first company that has characterized the tumor antigens that are highly expressed on brain tumor cancer stem cells and have designed vaccine specifically to target those cells.

Q: How have you been able to be so careful with investor dollars versus some of your competitors during the usually expensive development process?

Dr. Manish Singh, CEO of IMUC: Current business model of spending 100-200 million dollars to get to a true inflexion point (Phase II data or Phase III trial) is just not sustainable as it doesn't give investors much upside. Our mantra is one should raise no more than 35-40 million dollars and primarily focus on innovative end of drug development and get to Phase II clinical data. If Phase II data is positive, one can create a situation with 5-10x return for investors as we have only raised $21 since inception four years ago. Our burn is very low as we have smaller salaries combined with higher equity packages which aligns economic interests of shareholders and management. In addition, we outsource everything to the best of breed providers although we try to negotiate them to a reasonable costs. This allows us flexibility, access to technologies and systems developed by others, and makes us nimble in accelerating product development.

Q: What are your biggest pending milestones?

Dr. Manish Singh, CEO of IMUC: Enrollment should be completed by Q2, 2012 followed by an interim analysis in Q4,2012/Q1,2013 which can give us great insights in how well the trial is working. In addition, we plan to launch two more INDs in the next nine months.

Q: What are your biggest challenges?

Dr. Manish Singh, CEO of IMUC: Our biggest challenge is to do these developments with limited resources as that is only way to create larger returns. We have a team of only seven people, but have experience with over 25 clinical compounds in the last 20 years. We have developed a culture of innovation, collaboration, consensus, respect and frugality, and it is difficult to maintain that as you grow in size. By keeping the team small, we all are bursting at seams with things we are doing. However, there is passion and persistence in all of us to do this better than other companies with larger resources.

Q: Are there some things investors should be aware of regarding ImmunoCellular Therapeutics, that perhaps they are not?

Dr. Manish Singh, CEO of IMUC: Our Phase I data is often looked as a single center and small cohort data without any control, but we do have data comparing ICT-107 to a tumor lysate vaccine in the same patient setting, and have demonstrated significant survival improvement of 18 months over the tumor lysate trial. All patients in these two trials went through similar surgeries with same surgeons and had similar age and health thus minimizing biases of single center trial. We see a lot of physicians who treat glioblastoma patients very excited about our trial results and Phase II trials. The value of this company will sky rocket if we see even half good as results in this Phase II study.

In wrapping up, I'd like readers to know that II have reached out to other CEOs and companies whose vaccines appear (as well as others' whose vaccines were mysteriously absent) from the Special Report in Fierce Biotech. You may expect some follow up as I gather more information and wait for responses from my inquiries

MFG
Chali  

 

Habe meinen "Einkaufsplan" korriegiert und Galena +-0% wieder verkauft,den Kauf auf ende 2012 verschoben,den Kauf von ISCO auf 2013 verschoben und bin jetzt erst mal hier rein:

The Fight Against Brain Cancer
Glioblastoma multiforme is considered to be the most aggressive and, unfortunately, most common type of brain cancer. With a median survival time of a little over a year, prognosis is very poor even with standard care. There has been a dearth of significant treatments due to complications surrounding tumor cell resistance and brain vulnerability.
ImmunoCellular's blockbuster-to-be, ICT-107, may just be the best answer in development. Featured as one of the "100 Great Investigational Drugs," this cancer vaccine fights against glioblastoma by a three step process: (1) extract dendritic cells, (2) add tumor-associated antigens to them, and (3) inject them back into the patient to activate the immune system. Thus far, the vaccine has shown incredible results.
In the Phase I study, overall survival was 80% after 2 years and 55% after 3 years when the vaccine was applied. This compares to corresponding figures of 26.5% and 16% for standard care - a statistically meaningful difference. PFS after 2 years with use of ICT-107 was also 49.2% versus 10.7%. After four years, 19% of the patients using the drug were disease-free. The Phase II double-blind study is currently underway, and management will be announcing interim results likely at the end of 2012. The results thus far are nothing short of breakthrough.

Furthermore, from a competitive point of view, ICT-107 is able to be produced cheaper and with better logistics than analogous drugs. For example, Bristol-Myers Squibb's (BMY) Ipilimumab treatment for melanoma prices at around $30,000 per dose (see below for more). ICT-107 is anticipated to be available at a significantly lower cost and with less potential side effects.
And then there is the ImmunoCellular's solid antibody program, which is likely to gain partnerships due to the safe upside. ICT-121 holds promise in a variety of cancers, including pancreatic, brain, lung, colon, melanoma, renal, and breast forms. Meanwhile, ICT-109 has demonstrated solid preclinical efficacy in treating some pancreatic and lung cancers.

MFG
Chali  

ImmunoCellular Therapeutics Issues Letter to Shareholders

ImmunoCellular Therapeutics (OTCBB: IMUC) issued the following Letter to Shareholders today:

Dear Shareholder:

ImmunoCellular Therapeutics had its strongest year yet in 2011, starting with the initiation of a Phase II study of our lead product candidate, ICT-107, and the announcement shortly thereafter of one of the largest financings in our company's history. Many of the developments during 2011 have positioned the company for success in 2012. For example, we recently raised $10.4 million through a public offering underwritten by Cowen & Co. with Summer Street Research Partners acting as co-manager. With the completion of this offering, the company is now well financed to continue its planned operations at least through the end of 2013. In addition to fortifying our balance sheet, this financing signals investor confidence not only in our recent progress, but also and more importantly in our ability to continue our strong performance in 2012.

I wanted to share some of the key developments that we look forward to accomplishing for this year, so you can see why the ImmunoCellular Management team and many investors are so excited:

1. Completion of enrollment of Phase II clinical trial for ICT-107.

2. On the same scientific principles of targeting cancer stem cells like ICT-107, we are also moving towards developing a second vaccine (ICT-140) which will target ovarian cancer. Just like glioblastoma (GBM), ovarian cancer is known to respond well to immunotherapy. We are working with some of the leading academic investigators on designing a trial and hope to bring this into the clinic in 2012.

3. In-licensing of several antigens that could be incorporated into ICT-140 and other products down the road from major medical centers in US.

4. We have been working over the last few years on targeting CD-133, which is one of the most ubiquitous markers present on cancer stem cells not only in GBM but also in pancreatic, breast, ovarian and other solid tumors. We plan to start a new clinical trial for ICT-121 this year for recurrent GBM and potentially move to other indications over time.

Now, I would like to share with you some of the corporate highlights from last year, which we believe have positioned the company to achieve some of the milestones I outlined above:

FINANCING

-- Strengthened balance sheet. In February 2011, we completed a private placement through which we raised $8.1 million. Through this financing, we welcomed many leading life-science investors to our shareholder base and substantially strengthened our balance sheet. In addition, we raised an additional $10.4 million in January 2012 from several high quality healthcare focused investors. Post this financing, we have over $16 million in cash reserves to fund our operations, which we believe should be sufficient for the next 24 months. While pipeline advancement has increased our research and development expenses, we continue to be conservative in our cash burn rate by maintaining a lean infrastructure, staying focused on product development while outsourcing basic research to leading specialty service providers. This business model has proven to be extremely capital efficient and a source of strategic strength in challenging economic times.

CLINICAL DEVELOPMENT

-- Initiation of Phase II ICT-107 study in GBM. In January 2011, we announced the Food and Drug Administration's acceptance of our Investigational New Drug application to commence a Phase II study of ICT-107, our lead dendritic cell-based vaccine candidate for the treatment of GBM. To date, we have initiated the trial in 23 centers, including some of the top brain tumor treatment centers across the country. There are currently more than 115 patients enrolled in the study, with an estimated 160-200 to be enrolled in total in order to treat 102 patients with HLA-A1/A2 immunological subtypes. We expect to complete enrollment by Q2, 2012 and conduct interim analysis when 50% of events have occurred (32 deaths for interim analysis as the trial is designed to observe 64 events for the final analysis).

-- Robust Phase I survival data. Progression-free and overall survival times for GBM patients treated with ICT-107 continue to be substantially longer than those associated with standard of care (SOC) alone. In September, we reported three-year data indicating an overall survival of 55%, compared to 16% based on historical SOC. Of the 16 newly diagnosed patients who received ICT-107, 38% continue to show no tumor recurrence after three years, compared to the historic disease-free survival rate of 6% with SOC. Out of these patients, 19% remain disease-free after more than four years. No serious adverse events due to treatment have been observed to date.

-- Correlation between survival and antigen expression. The data we presented at ASCO also demonstrated a correlation between progression-free survival and expression of certain antigens on tumors targeted by ICT-107. Overall survival and progression-free survival are typically the primary endpoints in pivotal oncology clinical trials. Additionally, we demonstrated a decrease in cancer stem cell (CSC) populations in a few patients who received vaccination. This finding validates our mechanism of targeting CSCs from GBM tumors, and immunotherapy as a safe and effective means of doing so.

BUSINESS & INTELLECTUAL PROPERTY DEVELOPMENT

-- Manufacturing agreement with Progenitor Cell Therapy. In October, we retained the services of Progenitor Cell Therapy (PCT), an internationally recognized cell therapy services and development company and a wholly-owned subsidiary of NeoStem, Inc., to serve as the second manufacturing site to produce ICT-107. As part of this agreement, PCT will transfer and qualify the cGMP manufacturing process for ICT-107 at PCT's West Coast facility in Mountain View, California for use in our Phase II study, and provide subsequent manufacturing to support future trials and development efforts.

-- Strategic collaboration with BioWa. In June, we entered into an agreement with BioWa, Inc. to use BioWa's patented POTELLIGENT (R) Technology platform to develop antibody-dependent cellular cytotoxicity enhanced antibodies. We believe these enhanced versions of our proprietary antibodies will prove to be valuable partnering assets as we continue pursuing business development opportunities for these broadly applicable therapeutic candidates.

-- Launch of Caerus Discovery. Also in collaboration with BioWa, we announced the launch of Caerus Discovery, LLC, a new, privately owned biotechnology company based on the Prince William campus of George Mason University. In this joint venture, BioWa will fund drug-target discovery and antibody development activities using our proprietary monoclonal antibody technologies.

-- Patent portfolio expansion. Last year, we received two new patents and were granted allowance on one of the key patents on ICT-107 which covers method of treating neural cancers with these antigens and another allowance on a patent targeting cancer stem cell antigens for glioblastoma, expanding the company's issued patent portfolio to nine, with more than 18 additional patents pending. One of the new patents relates to the use of the therapeutic antibody candidate ICT-69 in the treatment and detection of multiple myeloma and ovarian cancer; the other covers the use of dendritic cells for the treatment of brain cancers, when used in combination with chemotherapy.

-- Recognition of ICT-107 by several sources. ICT-107 was included among R&D Directions' "100 Great Investigational Drugs" and Windhover's "Top 10 Licensable Oncology Products." It was also featured as a "promising vaccine" for brain cancer treatment on CBS News, and highlighted as one of the top ten therapeutic cancer vaccines by Fierce Biotech. While patient benefit and shareholder value will always be the primary measures of our success as a company, this positive recognition from multiple independent sources attests to the growing confidence of both clinicians and investors in our ability to develop novel therapeutics that significantly improve clinical outcomes for patients with cancer.

-- Leadership position in cancer stem cell therapeutic development. There is a growing evidence of the role cancer stem cells play in cancer recurrence and metastasis and the financial community is starting to realize this could change the paradigm of cancer treatment. We are being increasingly recognized as one of the leading players in this field with a phase IIb clinical program and have presented at numerous scientific and investment conferences on our progress and differentiation in the market.

With financing completed earlier this year and two years of cash to support these programs, we expect to be able to stay the course in developing the next generation of immunotherapy products. These could potentially be game changers in treatment of patients with brain and other cancers with large unmet medical needs.

With encouraging data from our Phase I study of ICT-107 in GBM, solid progress in Phase II enrollment, a broad intellectual property estate, and a new strategic collaboration related to our antibody therapeutics program, we are excited about where we are today.

Last, but not least, I would like to thank you, our shareholders, for your ongoing support as we continue to work toward our goal of becoming the preeminent developer of cancer stem cell therapeutics. We look forward to updating you on our continued progress toward this goal in the year ahead.

Best regards,

Manish Singh, Ph.D.

President and CEO  

http://seekingalpha.com/article/...er-stem-cell-biotechs?source=yahoo

Big Pharma wachsenden Appetit auf Krebsstammzellen Biotechs

Mit einer Marktkapitalisierung von rund 100 Millionen Dollar, ImmunoCellular Therapeutics ( IMUC.OB ) und seine Weiterentwicklung CSC-Pipeline wurde für Anleger zunehmend und Big Pharma Interesse in den letzten Monaten wie durch seine Lager angegeben Vorfeld ab 10. Januar die 1,05 $ auf den aktuellen 2,75 $ zu Marktpreisen schließen am 2. März. Dieses Interesse wird wahrscheinlich durch seine beeindruckende ICT-107 Ergebnisse der Phase I zur Behandlung von neu diagnostiziertem Glioblastom angeheizt. Die Daten waren beeindruckend auf einem 16-Reihe von Patienten mit neu diagnostiziertem GBM, die drei Injektionen des Impfstoffes nach dem Standard of Care behandelt wurden. Median OS für den Patienten Satz war 38,4 Monate mit einem medianen PFS von 17 Monaten. Die Drei-Jahres-OS für den Patienten Satz betrug 55% bei 6 Patienten ohne Wiederauftreten des Tumors nach drei Jahren. 19% waren noch krankheitsfreien nach vier Jahren mit einer Patientin nun nach 5 Jahren von PFS. Diese Daten waren erstaunlich in Anbetracht der aktuellen Prognose für GBM ist ca. 3 Monate mediane Gesamtüberleben mit keiner Behandlung und ca. 15 Monaten bei den derzeitigen Therapiestandard. Eine Phase II-Studie wurde Q4 2011 eingeleitet und wird etwa 200 Patienten an etwa 24 Standorten in den USA einschreiben Nach der jüngsten Aktualisierung Unternehmen , mehr als 120 Patienten wurden bereits eingeschrieben, und das Unternehmen plant, Einschreibung vor dem Ende des 2. Quartals abschließen 2012. Die Patienten werden mindestens vier Impfungen von IKT-107 zusätzlich zu dem derzeitigen Therapiestandard mit vorläufiger Datenanalyse Release im 1. Quartal 2013 erhalten. Eine Phase I-Studie über IKT-121 wird auch in diesem Jahr zum initiieren rezidivierendem GBM, die Förderung der BASF-Pipeline und damit Tiefe.

Big Pharma ist wahrscheinlich, beäugte das Unternehmen ein und versucht, festzustellen, ob das Chance / Risiko sagt jetzt zu kaufen oder ein Risiko für das 1. Quartal 2013 warten vorläufigen Daten und die Prämie zahlen sie gezwungen, da die Investoren den Preis treiben und Wettbewerber Angebot gegen sie wären. Zusätzlich zu dem Wert des Unternehmens, das Unternehmen vor kurzem angekündigt, ihre Patentportfolios Expansion auf insgesamt 9 mit 18 Patente angemeldet, den Schutz seiner Technologie und ihre Sicherung für die künftige Entwicklung und potenziellen Lizenzpartnern. 2012 ist in vollem Gange, die Phase-2-ICT-107-Studie ist in vollem Gange, 18 Patente sind angemeldet hinaus sind auch andere Katalysatoren wahrscheinlich und die Aktie bis offensichtlich laufen bedeutet Investor Kauf ist im Gange; alles was auf eine fortschreitende Preisschild für ImmunoCellular Therapeutics.

Disclosure: Ich habe keine Positionen in irgendwelchen Aktien erwähnt, kann aber eine Long-Position in initiieren IMUC.OB in den nächsten 72 Stunden.
: Dieser Artikel ist mit dem Stichwort Long & Short Ideen , Quick Picks & Listen  

kennt jemand die Gründe für den Anstieg?  

Das Volumen ist ja nicht gerade berauschend momentan...
Ich denke hier reicht eine gute Meldung und die Rakete geht ab.
Was meint ihr?  

 

Was ist hier los? Wo ist die Meldung?  

 

 

ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union

http://www.prnewswire.com/news-releases/...opean-union-247031671.html